eligibility_summary
Eligible: Untreated DLBCL, MZL, or MCL (non‑GCB in expansion), measurable lesion, ECOG 0–2, life ≥6 mo, adequate labs, for DLBCL expansion IPI ≥2. Negative pregnancy test, contraception, consent. Exclude: R‑CHOP intolerance/allergy, CNS/PMBL/PCNSL, DLBCL with prior indolent lymphoma/FL, prior transplant, recent major surgery/other trials, bleeding disorder/warfarin, strong/mod CYP3A drugs, other malignancy, anthracycline ≥150 mg/m2, serious cardiac/medical disease, active HBV/HCV/HIV/syphilis, absorption issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib trial in newly diagnosed B-cell NHL (non-GCB DLBCL, MCL, MZL) tests rocbrutinib (LP-168), a next-generation small-molecule Bruton tyrosine kinase (BTK) inhibitor that blocks B-cell receptor (BCR) signaling, combined with R-CHOP. Rituximab: anti-CD20 monoclonal antibody (biologic) inducing ADCC/CDC and apoptosis of CD20+ B cells. Cyclophosphamide: alkylating agent causing DNA crosslinks. Doxorubicin: anthracycline/topoisomerase II inhibitor generating DNA damage/ROS. Vincristine: vinca alkaloid microtubule inhibitor arresting mitosis. Prednisone: glucocorticoid inducing lymphocyte apoptosis. Targets/pathways: malignant B cells via CD20 and BTK/BCR signaling, DNA replication/repair (alkylation, topo II), microtubule dynamics, and glucocorticoid receptor–mediated apoptosis.